Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$32.51 USD
-4.22 (-11.49%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $32.50 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Apellis Pharmaceuticals, Inc. (APLS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$69.29 | $96.00 | $41.00 | 88.65% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Apellis Pharmaceuticals, Inc. comes to $69.29. The forecasts range from a low of $41.00 to a high of $96.00. The average price target represents an increase of 88.65% from the last closing price of $36.73.
Analyst Price Targets (17)
Broker Rating
Apellis Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.53 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 1.53 a month ago based on 17 recommendations.
Of the 17 recommendations deriving the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 70.59% and 5.88% of all recommendations. A month ago, Strong Buy made up 70.59%, while Buy represented 5.88%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.53 | 1.53 | 1.53 | 1.53 | 1.53 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/9/2024 | UBS | Eliana Merle | Strong Buy | Strong Buy |
8/2/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
8/2/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
8/2/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
8/1/2024 | Wedbush Securities | Laura Chico | Hold | Hold |
7/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/17/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Strong Buy |
7/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/28/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Hold | Hold |
6/28/2024 | Robert W. Baird & Co. | Colleen M Kusy | Strong Buy | Strong Buy |
6/4/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/31/2024 | Piper Sandler | Biren Amin | Not Available | Hold |
5/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/30/2024 | Raymond James | Steven Seedhouse | Strong Buy | Strong Buy |
4/18/2024 | Wells Fargo Securities | Derek C Archila | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.53 |
ABR (Last week) | 1.53 |
# of Recs in ABR | 17 |
Average Target Price | $69.29 |
LT Growth Rate | 39.90% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.30 |
APLS FAQs
Apellis Pharmaceuticals, Inc. (APLS) currently has an average brokerage recommendation (ABR) of 1.53 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms.
The average price target for Apellis Pharmaceuticals, Inc. (APLS) is $69.29. The current on short-term price targets is based on 11 reports.
The forecasts for Apellis Pharmaceuticals, Inc. (APLS) range from a low of $41 to a high of $96. The average price target represents a increase of $113.13 from the last closing price of $32.51.
The current UPSIDE for Apellis Pharmaceuticals, Inc. (APLS) is 113.13%
Based on short-term price targets offered by 17 analysts, the average price target for Apellis Pharmaceuticals, Inc. comes to $69.29. The forecasts range from a low of $41.00 to a high of $96.00. The average price target represents an increase of 88.65% from the last closing price of $36.73.